Aeterna nach dem Split

sehe bei der ING Bank 15 min zeitversetzt... hatte die Nasdaq Seite nicht auf.. jetzt schon :-)  

 

liebe Biotech!
Vielleicht mach ich die Johnnie Walker Green Label ja heute noch auf!  

jeder weiß das der wert ein spielwert ist und nicht sein vermögen hier investiert entweder Phase 3 funtzt oder eben nicht so einfach kann börse sein einfach mal die emotionen weg lassen und die welt der börse sieht ganz anders aus  

auch wenn es noch eine weile dauern kann ( wird ),diese Aezs wieder up gehen, hier wird einfach Geduld gefragt! mMn
Zur Info ich hänge auch noch dicke drin! Hab hier noch was aktuelles vom Freitag gefunden, vielleicht bringt das wieder einen Aufschwung :-)


KALAMAZOO — Armune Bioscience Inc. raised nearly $9.1 million in a capital round to support further commercialization of a blood test to screen for prostate cancer.

Part of a $9.4 million Series A capital raise, the funding in the Kalamazoo-based firm came from 46 investors, according to a regulatory filing this week with the U.S. Securities and Exchange Commission.

Formed in 2008, Armune Bioscience this year intends to begin raising a subsequent $25 million in Series B growth capital after launching its Apifiny diagnostic blood test last April.

Since signing a deal in December with Quebec City-based Aeterna Zenteris Inc. to co-market Apifiny, Armune has secured a number of deals with labs and provider networks to extend the blood test’s deployment across the U.S. and globally. In the latest agreement, announced Jan. 27, Scottsdale, Ariz.-based Fortified Provider Network will make the Apifiny test available to the more than 69 million members.

Using technology licensed from the University of Michigan, Apifiny checks for biomarkers that indicate the presence of prostate cancer in men with an elevated level of prostate-specific antigen, or PSA. The test works by detecting the antibodies produced when the body’s immune system recognizes a cancer antigen.

“The marketplace is demanding solutions beyond PSA-based testing for prostate cancer detection,” CEO David Espisito said in an announcement on the Fortified deal. “Apifiny is well positioned to offer clinicians additional information in the assessment of prostate cancer risk and help to address our health care system’s demand for improved outcomes at lower costs.”

In the first 10 months on the market, Armune performed more than 3,600 billable tests ordered by 325 primary care physicians and urologists in 25 states. Beyond detection, Armune is developing tests that it could bring to the market in the next two years for patient prognosis and treatment monitoring. Armune is also doing early discovery on tests to detect breast and lung cancers that could launch by 2019.


Gruß
 

zur Erinnerung, wir haben hier noch ein Gap zu closen !!


also lieber doddi gibt Dir mal ein bisschen Mühe jetzt die Tage ;-)


 

sollte das Gap geschlossen werden ;-)

Frage mich aber echt wie lange es jetzt dauern wird, bis der Kurs anspringt und ob überhaupt Investoren gefunden werden.  

das sind Dollar :-)
Investoren werden bestimmt gefunden bei der Pipeline mMn.

Gruß  

ja von August das, aber stepbystep alex ;-)


nach oben gibts es noch einige :-)  

Anzahl der Aktien mal nicht mehr beweglich sondern auf längere Sicht einfach mal feststehend ist (oder wenigstens zum Löwenanteil), wird klar werden , wie günstig AEZ ist. Ich glaube diese Zahl muss einfach mal fix sein, damit die Spielerein hier einem ordentlichen Volumen weichen.

Man kann jetzt wieder x Vergleiche heranführen, wo genau das überall auch schon passiert ist. Und dann stellt man fest, dass AEZ ja sogar noch zusätzlich ordentlich Cash und imminente PHASE 3 - Produkte hat...uppps !  

Quelle
http://finviz.com/quote.ashx?t=AEZS
Shs Outstand 10.17M
Shs Float 9.91M  

und was bedeutet das für uns?  

vordergründig ist das nur eine Info darüber, wieviele Shares nun dazugekommen sind. beeinfluss ja die MK. Und da ariva mit dem nachpflegen derselben nicht grade schnell bei der Sache ist...

vielleicht reagieren sie in USA schneller, mal schauen! :)  

Auf die Angabe der Sharezahl einer freien Plattform ? LOL

Erst einmal sollte Dodd den Fortschritt seiner Verwässerung verkünden, wo man absehen kann, wann die Orgie endet !
Dieser Zustand schreckt jeden Investor ab, da man nicht weiß, wie lange hier gewandelt wird.
Da haben sie sich schöne Eventualitätenkonstrukte mit den Fristen einfallen lassen.

Klar ist es unterbewertet, aber hier fehlt der Abschluß der KE.  

ähnlich. auch wenn die "Verwässerungsbeiträge" zur Aktienzahl sicherlich diesmal überschaubarer ausfallen sollten als bei der letzten KE, ist es immer noch ein Unsicherheitsfaktor . Wenn das größtenteils durch ist, sollte auch der Kurs steigen. Die Bewertung bleibt auch dann lachhaft, wenn wir irgendwo zwischen 12-15 Mio Aktien landen.

das bereits ?

http://mibiz.com/item/23367-armune-bioscience-of-kalamazoo-secures-

...zählen andere Dinge.

Obwohl man die Partnerschaft nicht überbewerten sollte, da die Tests erst 3600 Patienten erreichten.
Aber man gibt sich hoffnungsvoll, hier den Schnelltest voranzubringen .
Leider kennen wir die gebührenhöhe nicht.

Es sind trotzdem kleine Bausteine.  

schwerpunktmässig ankommt, ist klar. aber man sollte auch so kleine Dinge nicht unbeachtet lassen, denn es lässt auch Rückschlüsse zu, wie weit sich AEZ vernetzt und seine Kompetenzen ausbaut. Und Armune scheint ja Potential zu sehen,wenn man schon dafür einiges an Geld in die Hand nimmt.

..sind wichtig, um das Haus wachsen zu lassen.. Und manchmal sind sie der Beginn von etwas Größerem.. :-))  

könnte schon mal wieder eine überraschung geben! ;)  

http://www.scbio.org/event-2145638

Er wird sicher auch genau zu hören, was Doddy von sich gibt !  

http://www.businesswire.com/news/home/20160223005349/en/  

Aeterna Zentaris Commences Promotional Activities for APIFINY® Prostate Cancer Blood Test
February 23, 2016 08:30 AM Eastern Standard Time

CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) today announced that it has started promoting APIFINY®, the only cancer specific, non-PSA blood test for the evaluation of the risk of prostate cancer, in 20 U.S. territories pursuant to its co-marketing agreement with Armune BioScience, Inc.

Under the co-marketing agreement, the Company will promote APIFINY to designated medical professionals and will receive a commission for each test performed resulting from its targeted promotion. Jude Dinges, Senior Vice President and Chief Commercial Officer of Aeterna Zentaris, commented: “Our sales force has initiated the promotion of APIFINY, the only cancer specific, non-PSA based blood test available today. Given its ability to measure the immune-system response to prostate cancer, we believe APIFINY represents an important addition to clinical information for patients and their clinicians pertaining to the risk assessment for prostate cancer.”

About Prostate Cancer

Other than skin cancer, prostate cancer is the most common cancer in American men. The American Cancer Society predicted that 220,800 new cases of prostate cancer in the United States would occur in 2015, that there would be 27,540 prostate cancer deaths during the year and that one man in seven would be diagnosed with prostate cancer during his lifetime. Approximately 60% of prostate cancer is diagnosed in men aged 65 or older, and it is rare before age 40. Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 2.9 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.

About APIFINY®

APIFINY is the only cancer-specific, non-PSA blood test that is designed to aid clinicians in the risk assessment for prostate cancer. APIFINY technology measures the body’s immune response to cancer and is based on the measurement of eight prostate-cancer-specific autoantibodies in human serum. These autoantibodies are produced and amplified by the immune system in response to the presence of prostate cancer cells. The autoantibodies are stable and, because of their amplification, are likely to be abundant and easy to detect, especially with small tumors characteristic of early-stage cancers. The autoantibody markers span a range of biological functions integral to prostate-cancer progression. Cell cycle, structure, and cellular signaling pathways are all represented. The use of APIFINY results supplement other information about a patient’s risk of prostate cancer and may therefore aid clinicians in the detection of prostate cancer.

About Armune BioScience

Armune is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for cancer. The Armune BioScience Laboratory is a commercial reference laboratory, certified and regulated by the federal Clinical Laboratory Improvement Amendments (CLIA) law established in 1988. The laboratory’s CLIA Certificate permits it to perform APIFINY and other high-complexity medical tests. Armune, a private company, has a corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI. For more information, visit www.armune.com.

About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of or licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words “expects,” “believes,” “intends,” “anticipates,” and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

Contacts

Aeterna Zentaris Inc.
Philip A. Theodore
Senior Vice President
843-900-3223
ir@aezsinc.com